Large analysis of genes and proteins in lung adenocarcinoma points to possible new diagnostic and treatment approaches, and also reveals signatures of chemical exposures in patients who have never smoked.
Steve Carr and Claudia Ctortecka of the Proteomics Platform discuss recent advances from their group that can spur new research and the kinds of collaborations they are looking forward to.